Member Info for avctIPmatters

Matthew Vincent : Close previous connection with Tufts /Avacta/PB is listed on patents .

https://patents.justia.com/inventor/matthew-p-vincent

Very old news current situation

http://affyxell.com/company/people.php

Fyi : Think Brian might be busy :good luck .

"

Christina Coughlin

@coughlin582

·

12m

We are thrilled to welcome Brian to the Leadership team at Avacta. His knowledge and experience will combine to do great things for the Company

Welcome to Avacta Brian!"

#PeptidesCreateHope

#LetsDoThis

#HopeWithoutCompromise

Thanks for sharing : CEO "Look out for news on significant expansion plans with existing partners & more deals in the pipeline. Targeting further growth!"

gmcc

Avacta have a better solution :

https://x.com/Blueberrymgmnt/status/1878768151284027729

Informative info courtesy X

Innovating Oncology Treatment: The Role of ADCs and Strategic Partnerships in Shaping the Future of Cancer Care – An MIT Sloan Career Development Office Conversation with Ken Keller, Chairman of the Board, President, and CEO of Daiichi Sankyo, Inc.

https://cdo.mit.edu/blog/2025/01/08/innovating-oncology-treatment-the-role-of-adcs-and-strategic-partnerships-in-shaping-the-future-of-cancer-care-an-mit-sloan-career-development-office-conversation-with-ken-keller-chairman/

"In terms of innovative funding models, this need for speed and risk-sharing has driven early-stage companies, particularly those without the extensive resources of a Merck or AstraZeneca, to consider earlier alliances with larger companies. Mergers and acquisitions (M&A), as well as drug partnerships, are becoming more prominent as companies seek to leverage larger firms’ capabilities to stay competitive in this accelerated environment. Essentially, we’re witnessing a shift where partnerships and collaborations are not only a strategic choice but, in many cases, a requirement for sustained innovation and financial viability."

Nice spot LLP

"THRUST Strategic Communications

https://thruststrategiccommunications.com/

"LIFE SCIENCE STRATEGIC ADVISORY

DONE DIFFERENTLY

We are a team of specialized experts in biopharma finance, investor relations, and corporate communications.

Every THRUST advisor has been in-house at public companies and knows the in’s and out’s of strategic planning and building and implementing a comprehensive IR/PR program. With a unique focus on financing strategy and execution, and a demonstrated track record, we are more than your standard "IR shop."

We know what good looks like and how to get it done."

gmcc

Courtesy of :

https://x.com/Blueberrymgmnt/status/1877292845083578583/photo/1

Marty McFly

@Blueberrymgmnt

·

7m

#AVCT

$50m upfront

$1.15bn out turn

Preclinical candidate licensed by Avenzo to Duality based on *potential*.

“Based on preclinical studies, we believe AVZO-1418/DB-1418 has the potential to offer enhanced therapeutic benefits over other therapies.”

Alistair paid the price for bad execution - Securing the IP rights was his master stroke - affimers & Avacta pre|CISION® platform a proprietary warhead delivery system will eventually provide handsome investment returns. So wish him well & good luck .

Blame game is for losers - Believing in the science is for winners well worth the wait .

gmcc .

Getting on with the day job :

------------------------

Launch Diagnostics LimitedLaunch Diagnostics Limited

2,039 followers2,039 followers

23h • 23 hours ago

Respiratory season is well underway, with hashtag#UKHSA reporting a marked increase in hashtag#influenza positive rates in December 2024.

Influenza Typing is key in surveillance and gaining epidemiological data relating to circulating subtypes.

The Influenza typing PCR assays from hashtag#Anatoliageneworks allow for in house discrimination of of influenza subtypes, with wide instrument compatibility and simple workflow.

For further information please visit the Launch Diagnostics website or speak to your local territory manager.

https://www.launchdiagnostics.com/product/bosphore-influenza-typing-kit-v2/

https://lnkd.in/eeYBEipn

---------------------

David Wilson likes this

https://www.linkedin.com/in/davidswilson/recent-activity/reactions/

Launch Diagnostics France SASLaunch Diagnostics France SAS

291 followers291 followers

21h • 21 hours ago

Follow

A first case of Mpox clade 1b has been confirmed in Brittany. The patient has been in contact with people returning from Central Africa. (source Santé publique France).

Launch Diagnostics distributes the Mplex Mpox Test, Orthopox, Clade-1b: A multiplex PCR test specifically designed to detect the Clade-1b variant of the monkeypox virus.

hashtag#MpoxDiagnostics hashtag#PublicHealth hashtag#molecularbiology hashtag#mpoxvirus hashtag#Clade1bvariant hashtag#pcr hashtag#goldstandarddiagnostics"

gmcc

Correct : https://www.greywolftherapeutics.com/news/greywolf-appoints-darlene-deptula-hicks-as-chief-financial-officer

FYI https://x.com/foster_ideas/status/1876173806110421247/photo/1

gmcc

Wonder if Coris also sold . Anyway nice to see market cap increase . Still in paper deficit still a long way to go to break even however slow & steady increase next few months would be great - asset IP value remains very understated IMO .

Good luck gmcc .

Fyi :

Peter Thiel’s 7 Questions…and Why I Think Ondo Could Be a Billion-Dollar Company

Craig Foster

Craig Foster

CEO Ondo InsurTech Plc

January 3, 2025

https://www.linkedin.com/pulse/peter-thiels-7-questionsand-why-i-think-ondo-could-company-foster-zpw8e/

Fyi - adds cash to ONDO coffers approx £915k

"Ondo InsurTech Plc

@OndoPlc

·

Jan 2

Happy New Year from #ONDO!

#RNS this a.m. 4.16m warrants were exercised in December 2024. FYI Average strike price of warrants is approx 22p.

https://londonstockexchange.com/news-article/ONDO/total-voting-rights/16833589"

Good Morning

This is the blank form

https://assets.publishing.service.gov.uk/media/60102d06e90e071434ad0ae2/CC04-V1.1.pdf

Hopefully another step forward in Avacta becoming a pure Therapeutics company -with divest of Diagnostics .

Look forward to 2025 being a better year for shareholders .

gmcc

Note Avacta affimer patent update filed by AffyXell Therapeutics Co., Ltd. --- 18.12.2024

credit https://x.com/JStonker/status/1873424041249538236/photo/1

----------

"[0006] Affimer® , developed by Avacta, is a small stable protein molecule engineered based on a stefin A protein, which is an in-vivo protein. Affimer® includes two short peptide sequences having a random sequence and an N-terminal sequence, and is able to bind to a target material with high affinity and specificity in a manner similar to a monoclonal antibody. Affimer® shows remarkably improved binding affinity and specificity compared to the free peptide library, and has a very small size and high stability compared to antibodies, and is therefore receiving great attention as a next-generation alternative pharmaceutical platform to replace antibodies ( U.S. Patent Nos. 9447170 , 8853131 , etc.).

[0007] Against this background, the present inventors have made intensive efforts to develop a polypeptide that specifically binds to CD40L by engineering the natural stefin A protein. As a result, a stefin A protein mutant binding to CD40L with excellent affinity and specificity was invented. In particular, it was confirmed that the stefin A protein variant specifically binding to CD40L exhibits excellent inhibitory activity against CD40L."

https://worldwide.espacenet.com/patent/search/family/087564775/publication/EP4477665A1?q=pn%3DEP4477665

https://register.epo.org/application?number=EP23753222&lng=en&tab=family

"James Heseltine Deputy CFO & Company Secretary at Avacta Group plc

Been with the company since 2019 never missed any posting of accounts timelines - knows debits/credits etc - be ok for the time being .

-----------

Deputy CFO & Company Secretary at Avacta Group plc

Avacta

5 yrs 4 mos5 yrs 4 mos

Deputy CFO & Company Secretary

Full-time

Jun 2024 - Present · 7 mosJun 2024 to Present · 7 mos

Day-to-day responsibility for planning, implementing, managing, controlling and reporting on all financial activities of the Group.

Working with management teams across the Group to help define and execute their strategies and plans to meet the Group's objectives, including short and long-term financial planning and forecasting.Day-to-day responsibility for planning, implementing, managing, controlling and reporting on all financial activities of the Group. Working with management teams across the Group to help define and execute their strategies and plans to meet the Group's objectives, including short and long-term financial planning and forecasting.

Group Financial Controller

Group Financial Controller

Full-timeFull-time

Jan 2022 - Jun 2024 · 2 yrs 6 mosJan 2022 to Jun 2024 · 2 yrs 6 mos

Wetherby, England, United KingdomWetherby, England, United Kingdom

Group Accountant

Group Accountant

Sep 2019 - Jan 2022 · 2 yrs 5 mos

gmcc

FYI " Salivary Gland Cancer is very niche"

"The global salivary gland cancer treatment market size was valued at USD 1.65 billion in 2023 and is projected to reach USD 3.04 billion by 2031, with a CAGR of 7.90% during the forecast period of 2024 to 2031."

https://www.databridgemarketresearch.com/reports/global-salivary-gland-cancer-treatment-market

"The salivary gland cancer treatment market is witnessing steady growth, driven by advancements in diagnostics and innovative therapies. Treatment options have traditionally included surgery, radiation therapy, and chemotherapy, but new innovations are making treatments more effective and personalized. One significant trend is the increasing use of targeted therapies and immunotherapy, which focus on specific cancer cells while minimizing damage to healthy tissue. These therapies are improving patient outcomes, reducing side effects, and offering hope for patients with advanced stages of the disease. Additionally, the development of precision medicine is allowing for tailored treatment approaches based on genetic profiling, further enhancing the efficacy of treatments. As research progresses, these trends are expected to accelerate, leading to better management of salivary gland cancer."

gmcc

FYI Avacta clinical trials may benefit :

https://www.fda.gov/about-fda/oncology-center-excellence/oce-programs-and-projects-overview

( credit BMH @BMHLTD)

gmcc

Good Morning Should get early patient phase1b outcomes :

" Updated data for the Phase 1 dose escalation cohorts and the recommended dose for expansion cohort will be presented in the first half of 2025."

Looking at the Primary/Secondary Outcome Measures comprehensive testing of cohorts taking place . So if all goes to plan . No reason not to expect : £$ inflection points throughout 2025 . As i keep saying - Asset IP value is currently understated . Other pharma/institutions will want to be involved - Avacta technology will continue to demonstrate it does work. --- "Expanding the reach of highly potent cancer therapies with pre|CISION® is indeed an achievable objective - Obviously normal company administation matters also need progressing but that can be sorted

Good luck Avacta /clinicians /patients involved -

Have a good Xmas - look forward to a happy & prosperous new year everyone and remember it is only a message board not the be all & end all .

gmcc